Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (January 2026)
28 slides from Glaukos's investor presentation, Jan 13, 2026
Slide 1: Investor Presentation January 2026
Investor Presentation JANUARY 2026
Slide 2: Disclaimer
A B O U T G L A U K O S 2 © 2026 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements.
Slide 3: We'll Go First: Innovation at the core
A B O U T G L A U K O S 3 © 2026 Glaukos Corporation WE’LL Innovation is at the core of everything we do. We push the limits of science and technology to solve unmet needs in chronic eye diseases for the benefit of patients worldwide. Dropless Therapies Challenging conventional paradigms to advance
Slide 4: Best-in-Class Growth Company with Industry-Leading Pipeline
A B O U T G L A U K O S 4 © 2026 Glaukos Corporation Best-in-Class Growth Company with Industry-Leading Pipeline 13 Disclosed pipeline 12 programs Currently commercialized products iStent Micro-Scale iDose Sustained-Release iLin k Bio-Activa t e d iLution Eyelid Delivery Retina XR Bio-Erodible IVT O
Slide 5: Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities
A B O U T G L A U K O S 5 © 2026 Glaukos Corporation Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities Fundamentally resets how keratoconus is diagnosed, managed and treated to dramatically improve patient awareness and access to effective care INTERVENTIONAL KERATOCONUS Radically imp
Slide 6: Major Problem in Glaucoma Care: Non-Compliance with Topical Eye Drops
I N T E R V E N T I O N A L G L A U C O M A 6 © 2026 Glaukos Corporation Major Problem in Glaucoma Care: Non-Compliance with Topical Eye Drops 1 Nordstrom BL et al. Am J Ophthalmol. 2005;140(4): 598-606. % 90are non-compliant with topical drops 50~ % purposely discontinue topical drops within 6 mont
Slide 7: Glaukos is Ideally Positioned to Lead the IG Paradigm Shift
I N T E R V E N T I O N A L G L A U C O M A 7 © 2026 Glaukos Corporation Glaukos is Ideally Positioned to Lead the IG Paradigm Shift OCULAR HYPERTENSION ADVANCED MODERATE MILD REFRACTORY The IG workhorse: Foundational therapy across the entire disease stage spectrum For patients who have failed surg
Slide 8: iDose TR: Long-Duration Drug Therapy Addresses Patient Non-Compliance
I N T E R V E N T I O N A L G L A U C O M A 8 © 2026 Glaukos Corporation iDose TR: Long-Duration Drug Therapy Addresses Patient Non-Compliance Anchors securely into scleral tissue for continual elution of unique, highly concentrated travoprost directly into anterior chamber Designed to deliver up to
Slide 9: iDose TR is Just the Beginning
I N T E R V E N T I O N A L G L A U C O M A 9 © 2026 Glaukos Corporation iDose TR is Just the Beginning IG PARADIGM SLT PROCEDURAL PHARMACEUTICALS MIGS MIBS FILTRATION SURGERY Topical meds as bridge therapy • Designed to streamline insertion to help facilitate potential future in-office administrati
Slide 10: iStent infinite: Best-in-Class MIGS Therapy for Long-Term IOP Control
I N T E R V E N T I O N A L G L A U C O M A 10 © 2026 Glaukos Corporation iStent infinite: Best-in-Class MIGS Therapy for Long-Term IOP Control IG PARADIGM SLT PROCEDURAL PHARMACEUTICALS MIGS MIBS FILTRATION SURGERY Topical meds as bridge therapy 2012 Pioneered MIGS with iStent approval iStent techn
Slide 11: IG Represents the Next Wave for Comprehensive Ophthalmology Practices
I N T E R V E N T I O N A L G L A U C O M A 11 © 2026 Glaukos Corporation IG Represents the Next Wave for Comprehensive Ophthalmology Practices 1 Market Scope 2025 Glaucoma Surgical Device Report 2 Market Scope 2024 Glaucoma Pharmaceutical Report; includes glaucoma and OHT patients; assumes bilatera
Slide 12: Ophthalmic surgeons seek to offset cataract pro fee reductions
I N T E R V E N T I O N A L G L A U C O M A 12 © 2026 Glaukos Corporation Ophthalmic surgeons seek to offset continued cataract surgery pro fee reductions, helping to drive adoption and utilization of IG therapy 1 3 In-office injectable delivery of iDose and repeat administration approval can drive
Slide 13: Product Roadmap Underscores Extensive IG Product Depth
I N T E R V E N T I O N A L G L A U C O M A 13 © 2026 Glaukos Corporation Product Roadmap Underscores Extensive IG Product Depth PRODUCT PAT IENT ST A T US iStent / iStent inject / iStent inject W Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) iStent infinite Glaucoma (faile
Slide 14: Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities
A B O U T G L A U K O S 14 © 2026 Glaukos Corporation Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities Fundamentally resets how keratoconus is diagnosed, managed and treated to dramatically improve patient awareness and access to effective care INTERVENTIONAL KERATOCONUS INTERVENTION
Slide 15: Keratoconus: Debilitating, Sight-Threatening Rare Disease
I N T E R V E N T I O N A L K E R A T O C O N U S 15 © 2026 Glaukos Corporation Keratoconus (KC): Debilitating, Sight-Threatening Rare Disease Topical medications used as a supplement (“bridge therapy”) as needed OR KC is characterized by thinning and steepening of the cornea • Typical onset in teen
Slide 16: KC: Vastly Underdiagnosed, Misdiagnosed, Undertreated Disease
I N T E R V E N T I O N A L K E R A T O C O N U S 16 © 2026 Glaukos Corporation KC: Vastly Underdiagnosed, Misdiagnosed, Undertreated Disease Topical medications used as a supplement (“bridge therapy”) as needed 1 Kreps EO, et al. Cont Lens Anterior Eye. 2021:44(3):101 2 Based on annual Glaukos proc
Slide 17: Transformative Epioxa Therapy Ushers in New Standard of KC Care
I N T E R V E N T I O N A L K E R A T O C O N U S 17 © 2026 Glaukos Corporation Transformative Epioxa Therapy Ushers in New Standard of KC Care First and only FDA-approved epithelium-on treatment Incision-free, topical drug therapy catalyzed by oxygen and light Designed to slow or halt KC progressio
Slide 18: Significant Investment to Dramatically Improve KC Patient Access
I N T E R V E N T I O N A L K E R A T O C O N U S 18 © 2026 Glaukos Corporation Rare Disease: Significant Investment to Dramatically Improve KC Patient Access Patient Education Advocacy Engagement Provider Awareness, Detection Centers & Tools Patient Service & Market Access Support Integrated IT Dep
Slide 19: Launch Timing for Epioxa & New Rare Disease Infrastructure
I N T E R V E N T I O N A L K E R A T O C O N U S 19 © 2026 Glaukos Corporation Launch Timing for Epioxa & New Rare Disease Infrastructure 1Q 26 2Q 26 3Q 26 4Q 26 2027+ Go live with patient service and support hub Drug availability/launch Establish site of care network Establish payer coverage Suppo
Slide 20: Next Game-Changing Program: Customized, Spherical Therapy for KC
I N T E R V E N T I O N A L K E R A T O C O N U S 20 © 2026 Glaukos Corporation WHAT IF? CUSTOMIZED, SPHERICAL THERAPY Use biomechanical modeling to deliver customized, patterned treatment that matches each patient’s unique corneal topography Use proprietary algorithm to precisely target UV energy f
Slide 21: Product Roadmap for Sustained Leadership in Effective KC Care
I N T E R V E N T I O N A L K E R A T O C O N U S 21 © 2026 Glaukos Corporation Product Roadmap for Sustained Leadership in Effective KC Care PRODUCT PAT IENT ST AT US Photrexa (Epi-off) Keratoconus FDA Approved (2016) Epioxa (Epi-on) Keratoconus FDA Approved (2025) iLink 3rd Generation Keratoconus
Slide 22: Novel Eyelid Drug Delivery Platform Spearheads Entry into Anterior Segment
i L U T I O N P L A T F O R M 22 © 2026 Glaukos Corporation Novel Eyelid Drug Delivery Platform Spearheads Glaukos’ Entry into Anterior Segment Part D Pharmaceuticals 1 O'Dell L, Dierker DS, Devries DK, et al. Psychosocial Impact of Demodex Blepharitis. Clin Ophthalmol. 2022;16:2979-2987 2 Publicly
Slide 23: Retina XR: Biodegradable Implants for Long-Duration Efficacy
R E T I N A X R P L A T F O R M 23 © 2026 Glaukos Corporation Biodegradable Implants Designed to Provide Long-Duration Efficacy 1 Market Scope 2 Long-term Experience With Intravitreal Anti-VDGF Treatment in Patients with AMD: Analysis of IRIS Registry Database (presented at 39th Annual Meeting of th
Slide 24: Disrupting Paradigms with One of the Industry's Most Formidable Portfolios
A B O U T G L A U K O S 24 © 2026 Glaukos Corporation Disrupting Paradigms with One of the Industry’s Most Formidable Portfolios P R O D U C T P A T I E N T S T A T U S iStent / iStent inject / iStent inject W Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) GLAUCOMA iStent in
Slide 25: Solid Financial Footing Supports Future Pipeline Delivery & Growth Plans
A B O U T G L A U K O S 25 © 2026 Glaukos Corporation Solid Financial Footing Supports Future Pipeline Delivery & Growth Plans N E T S A L E S 1 (in millions) 2022 2023 $315 $283 20%+ 10-year CAGR $383 2024 $5071 2025 G LO B A L I N F R A ST R U C T U R E 17Countries with direct operations 300+ Glob
Slide 26: We'll Go First
WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 27: Glaukos: Transforming Vision
GLAUKOS TRANSFORMING VISION
Slide 28: Appendix: GAAP to Non-GAAP Reconciliation - 3Q 2025
A B O U T G L A U K O S 28 © 2026 Glaukos Corporation Appendix 3Q 2025 GAAP Amort. of Dev Non-recurring 3Q 2025 Non-GAAP Gross Margin Tech Intangibles, Dev IP, and Dist Rights Write-down of Certain Inventory Gross Margin Net Sales $ 133,537 $ 133,537 COGS $ 28,831 $ (6,007) $ (1,303) $ 21,521 Gross